Biogen Inc
(BSP:BIIB34)
R$
169.49
1.36 (0.81%)
Market Cap: 149.37 Bil
Enterprise Value: 178.06 Bil
PE Ratio: 15.80
PB Ratio: 1.56
GF Score: 75/100 Biogen Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 02:40PM GMT
Release Date Price:
R$219.12
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. We're very pleased to have Biogen. Joining us today from the company is Chris Viehbacher, CEO. Chris, thanks so much for being here.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Well, thanks so much, Chris. I really appreciate the time today. I know it's a busy time at Biogen.
Questions & Answers
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Maybe to start, I thought we could talk about what's some of your key priorities are over the next year?
Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director
Yes. Thanks, Terence. It has been a busy, I think it's 8 months, maybe 9 months now. I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot